<DOC>
	<DOC>NCT00420238</DOC>
	<brief_summary>Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.</brief_summary>
	<brief_title>Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criteria Active and severe ankylosing spondylitis Ankylosing spondylitis refractory to standard antirheumatic treatment Between 18 and 70 years of age Exclusion criteria Prior exposure to any TNFinhibitor, including etanercept DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation Dose of NSAIDs changed within two weeks of study drug initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Axial Ankylosing Spondylitis</keyword>
	<keyword>Adult</keyword>
</DOC>